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The use of antithrombotic therapy of any type assumes
a thrombotic mechanism for the patient's brain isch-
emia. Typical, but by no means specific, clinical and
radiologic features of atherothrombotic, lacunar and
embolic brain ischemia are outlined. The indications for
anticoagulant therapy include progressing stroke and
cardiogenic brain embolus. According to previous ran-
domized trials, transient ischemic attacks should be
managed with aspirin, 1.0 to 1.5 g daily, pending the
results of studies of smaller aspirin doses and other plate-
This review summarizes the current knowledge and rec-
ommendations about antithrombotic therapy in patients with
ischemic cerebrovascular disease. The use of anticoagulants
or platelet-active agents is based on the assumption that
thrombosis within the heart or arterial system is an important
substrate of brain ischemia. In some circumstances. brain
ischemia occurs by mechanisms that may be only minimally
affected by antithrombotic therapy. For example, severely
obstructive lesions due to atherosclerosis or inflammatory
arteritis might best be managed by surgically removing the
flow-limiting plaque or by treating the inflammatory vas-
cular changes rather than by the use of anticoagulant agents
or platelet-antiaggregating agents. These examples also il-
lustrate the potential interaction of multiple pathophysio-
logic mechanisms in the ischemic brain. Thus. the decision
to use either anticoagulants or platelet-antiaggregating agents
is based on correct identification of the underlying patho-
physiology.
Classification and Pathophysiology of
Cerebrovascular Disease
Etiologic mechanisms. Cerebrovascular disease is typ-
ically classified by: 1) its temporal profile, for example,
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let-active drugs. In patients with a suspected cardiogenic
brain embolus, anticoagulation should be withheld pend-
ing the results of a computed tomographic scan done 24
to 48 hours from onset. If there is no evidence of hem-
orrhagic transformation or a large area of infarction and
the patient does not have sustained hypertension, hep-
arin therapy should be initiated in an effort to prevent
a recurrent embolus.
(J Am Coil Cardiol 1986;8:88B-97B)
transient ischemic attack or reversible ischemic neurologic
deficit; 2) the vascular territory involved, for example, mid-
dle cerebral artery, posteroinferior cerebellar artery or len-
ticulostriate vessels; and 3) the presumed etiology, for ex-
ample, atherosclerotic cerebrovascular disease, cardiogenic
brain embolism or intracerebral hemorrhage. In approxi-
mately 85% of patients presenting with an acute stroke, the
cause of the stroke will be ischemia, whereas in 15% the
cause will be intracranial hemorrhage (Fig. I). Of patients
with cerebral ischemia, the vast majority (almost 80%) are
presumed to have their ischemic stroke as a result of either
atherosclerosis of large brain arteries or degenerative oc-
clusion of small arteries. About 15% of patients with isch-
emic infarction sustain their stroke because of embolism of
an intracardiac thrombus. Only about 5% of patients will
have a stroke from other causes including arterial dissection,
alterations in coagulation, vasculitis or systemic hypoten-
sion. Clinical determination of the etiologic basis for stroke
in individual patients is occasionally clear, but more often
is obscure because of a number of factors, most notably the
insensitivity of clinical and laboratory methods and the fre-
quent coexistence of multiple, potentially etiologic factors.
Despite careful evaluation, up to 40% of patients with stroke
have no definite etiologic basis uncovered (I).
Clinical determination of etiology. One study (2) found
that about 33% of patients with acute stroke had evidence
of both a potential cardioembolic source of stroke and ath-
erosclerotic cerebrovascular disease; in half of these patients
it was impossible to determine which potentially etiologic
factor accounted for their stroke. "Gold standards" for the
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Figure 1. General framework for conceptualizing
the causes of stroke. The mechanisms are contro-
versial.
detennination of the underlying stroke etiology in individual
patients do not exist, and decisions must be based on a
constellation of the clinical computed tomographic, angio-
graphic, laboratory and cardiac characteristics possessed by
the individual patient. Further, the extent to which an oc-
clusive lesion of any origin produces brain ischemia is also
dependent on the adequacy of the collateral circulation to
the territory supplied by the occluded vessel. Thus, the
presence or absence of adequate collateral vessels accounts
for the observation that one patient with an internal carotid
artery occlusion may have a devastating cerebral hemisphere
infarction, whereas another with adequate collateral circu-
lation may sustain only a minor stroke or be totally asymp-
tomatic.
Clinical Characteristics of Atherothrombotic
Brain Ischemia
Atherothrombotic stroke. Atherosclerotic disease of
the cervical and large cerebral arteries may produce brain
ischemia by means of embolism of plaque material or plate-
let fibrin thromboemboli (artery to artery emboli) or through
the presence of a flow-restricting stenosis that may ulti-
mately lead to thrombus fonnation with occlusion. Certain
clinical and radiologic features, while suggestive of an ath-
erothrombotic basis for an ischemic event, are by no means
specific. The typical patient with brain infarction secondary
to atherothrombotic disease has a history of hypertension,
a history of a previous transient ischemic attack (about 50%
of cases) and experiences the stuttering onset, at night or
on awakening, of a focal neurologic deficit (3). Carotid
bruits are present in 10 to 20%. A computed tomographic
scan may show evidence of cortical infarction in the territory
supplied by a single cerebral artery. Noninvasive ultrasound
studies of the carotid arteries or cerebral angiography may
show atherosclerotic plaques of the carotid bifurcation and
intracranial vessels. However, these clinical features are not
specific. Patients who experience embolism to distal vessels
from thrombi originating from cervical atherosclerotic le-
sions (artery to artery emboli) may have the sudden onset
of a maximal neurologic deficit more characteristic of a
cardiogenic embolus (4,5).
Lacunes. Lacunes ("holes") are 0.2 to 15 mm3 infarcts
of the putamen, thalamus, internal capsule or pons. These
cerebral infarcts result from occlusion of the small pene-
trating vessels arising from the anterior, middle or posterior
cerebral arteries and the basilar artery (6,7). Hypertension,
present in about 75% of cases, is presumably the major risk
factor for the occlusive changes in these small arteries.
Thirty to 40% of patients with lacunar infarcts have diabetes
mellitus. The occlusive process is not one of cholesterol-
laden atherosclerosis of the large arteries, but rather of a
fibrinoid, lipohyalinotic degeneration. The clinical pattern
is one of a gradual or stuttering onset in up to 30% of
patients. Occasionally, there is a prior transient ischemic
attack. A number of specific "lacunar" syndromes have
been described, with the most frequent being pure motor
stroke, pure sensory stroke, ataxic hemiparesis and the syn-
drome of dysarthria/clumsy hand. The usual course is one
of good recovery of neurologic function.
Many lacunes demonstrated at autopsy or by computed
tomography are unassociated with any corresponding stroke
history (6,7). When bilateral lacunar strokes occur, pseu-
dobulbar palsy with severe dysarthria can result. Although
most small, subcortical strokes visible on computed to-
mography are lacunar as a result of degenerative penetrating
artery disease, there is an important caveat. Large or "giant"
lacunes (> 1.5 cm) of subcortical structures imply occlusion
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Study No. of FlU StrokelDeath Stroke
(Reference)/Year Therapy Palients (rna) No. (%) (%)
Baker et al. (19) Can 20 20 6 (30) 4 (20)
1962 AC 24 18 6 (25) 1(4)
Veterans Administration (20) Con 15 13 0(0) 0(0)
1961 AC 22 9 2 (9) I (5)
Baker et al. (37) Con 30 41 9 (30) 4 (23)
1966 AC 30 38 14 (47) 2* (7)
Pearce et al. (38) Con 20 II 4 (20) 2 (10)
1965 AC 17 II 1(6) 1(6)
Total Con 85 21 19 (22) 10 (10)
AC 93 19 23 (25) 5 (5)
*Three additional patients had a stroke after anticoagulant therapy was discontinued. AC = anticoagulant
therapy; Con = control; FlU = follow-up.
of adjacent penetrating arteries, and are often caused by
thrombi or emboli occluding the origin of these vessels.
Hence, giant lacunar strokes have little pathophysiologic
specificity.
Cardiogenic emboli. About 15% of ischemic brain in-
farcts are caused by cardiogenic emboli (4,8-11). These
emboli arise from thrombi formed on the mitral or aortic
valve, on the left ventricillar surface or within the left atrium.
One-third of patients with an ischemic stroke have evidence
of both atherosclerotic cerebrovascular disease and a po-
tential cardioembolic source (2). This coexistence of po-
tential etiologic factors leads to irreconcilable diagnostic
ambiguity in 50% of these patients. This diagnostic dilemma
is further heightened by the realization that some transient
cardiac arrhythmias such as paroxysmal atrial fibrillation
may produce an embolic stroke leaving no clues, as deter-
mined by our available diagnostic probes, to their existence.
The clinicalfeatures that suggest a cardiogenic embolism
include the sudden onset of maximal neurologic deficit while
the patient is awake and active without a history of ante-
Table 2. Aspirin Therapy in Patients With Transient Ischemic Attacks
Study No. of FlU StrokelDeath
(Reference)/Year Therapy Patients (rna) No. (%) p Value
CCSSG (40) PIa/SuI 295 26 68 (23) <0.05
1978 ASA 290 46 (16)
AICLA (29) Pia 204 36 31 (18) <0.02
1982 ASA 400 35 (10)
AITIA (41) Pia 90 24 19 (21) NS
(medical) 1977 ASA 88 13 (15)
AITIA (42) Pia 60 24 8 (13) NS
(surgical) (1978) ASA 65 8 (12)
ATIAIS (43) SuI 61 24 3 (7) NS
1982 ASA 63 3 (5)
Danish CS (44) PIa 102 25 17 (17) NS
1983 ASA lOl 21 (21)
Garde et al. (45) AC 114 20 7 (6) NS
1983 ASA 127 7 (6)
Reuther and Domdorf (46) Pia 29 24 4 (14) NS
1978 ASA 29 0(0)
Total Other 955 157 (16)
ASA 1.163 133 (II)
AC = anticoagulant; AICLA = Accldents-Ischemiques Cerebroux Lies iJ I'AtheroscIerose; AITIA
Aspirin in Transient Ischemic Attacks Study; ASA = aspirin; ATIAIS = Anturane Transient Ischemic Attack
Study; CS = Cooperative Study; CCSSG = Canadian Cooperalive Stroke Study Group; Dip = dipyndamole;
NS = not significant; Pia = placebo; S = sulfinpyrazone.
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Table 3. Dipyridamole in Patients With Transient Ischemic Attacks
No,
Study of F/U Stroke/Death Stroke
(Reference)/Year Therapy Patients (mo) No(%) No. (%)
Acheson et al. (48) Pia 84 25 17 (20) II (13)
1969 Dip 85 21 (25) 12 (14)
Guiraud-Chaumeil et al (47) Hyd 92 14 (15) 8 (9)
1982 ASA 102 36 9 (9) 6 (6)
ASA+Dip 105 11 (10) 7(7)
AICLA (29) PIa 204 36 37 (18) 31 (15)
1982 ASA 198 27 (14) 17 (9)
ASA+Dip 202 26 (13) 18 (9)
ACCSG (49) ASA 442 24 84 (19) 60 (14)
1985 ASA+Dlp 448 85 (19) 53 (12)
Total Other 1,122 188 (17) 133 (12)
Dip 840 143 (17) 90 (II)
ACCSG = American-Canadian Cooperative Study Group; AICLA = Accldents-Ischemiques Cerebroux
Lies a I'Atherosclerose; ASA = aspirin; Dip = dipyridamole; Hyd = hydergine; Pia = placebo.
cedent ipsilateral transient ischemic attacks. Cardiogenic
embolism is also suggested by the clinical or computed
tomographic demonstration of multiple brain infarcts in-
volving the cortex or cerebellum in multiple vascular ter-
ritories or by the occurrence of a systemic (non-central ner-
vous system) embolus (12-14). A potential cardiac source
of embolism should be particularly sought in patients youn-
ger than 50 years of age, those with hemorrhagic infarction
by computed tomography and those whose angiographic
studies demonstrate either vanishing occlusions of the major
intracranial arterial trunks or fail to show atherosclerotic
arterial changes. Only rarely will echocardiography, Holter
electrocardiographic monitoring or angiography demon-
strate an occult intracardiac source of embolus in the absence
of a strong clinical suspicion of cardiogenic embolism or a
suggestion of a cardiac abnormality by physical examina-
tion, chest roentgenogram or electrocardiogram (16,17).
Figure 2. Presumed mechanism of hemorrhagIC transformation
caused by distal migration of embolic fragments with reperfusion
of infarcted tissue. (Reproduced with permission from Toole JF.
Cerebrovascular Disorders. New York: Raven Press, 1984.)
Brain surface
Pressure restored
Zone of infarctIOn
AnemiC infarction
Embolism breaks up.
goes Into one branch
Antithrombotic Therapy in
Cerebrovascular Disease
Uncertainty abounds regarding the role of anticoagulant
and platelet-antiaggregating agents in patients with transient
ischemic attacks, completed strokes or progressing strokes.
The multiple pathophysiologic mechanisms of ischemic stroke
Figure 3. Cerebral angiogram showing vanishing occlusion of the
middle cerebral artery.
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Figure 4. A, Initial computed to-
mographic scan showing possible low
density area (arrow) in the left pari-
etal area. B, Follow-up scan showing
hemorrhagic transformation (arrow)
in area of previous infarction.
and their clinical definition have only recently been appre-
ciated. Older treatment studies have not considered these
specific mechanisms. The marginal and negative results of
many studies have undoubtedly been influenced by the
lumping together of all mechanisms into medical and sur-
gical treatment trials. Pending studies considering the di-
verse pathophysiologic spectrum of strokes, available treat-
ment qata are reviewed.
Completed stroke. The term "completed stroke" de-
scribes the situation where a focal brain ischemic event has
been persistent and stable for longer than 24 hours. Early
small randomized trials (19-27) of long-term anticoagulant
therapy in patients with completed stroke showed no sig-
nificant advantage to anticoagulant therapy in the reduction
of recurrent stroke and also suggested that the risks of death
and bleeding were increased in the anticoagulant-treated
groups. Thus, the use of long-term anticoagulant therapy in
patients with completed stroke has largely been abandoned
except for its use in those patients with cardiogenic emboli.
Proponents of short-term (5 to 7 days) heparin therapy for
clinically small or moderate size ischemic strokes hope to
prevent progressive stroke or stroke recurrence during this
high risk period. Although nonrandomized studies (1) sug-
gest this practice to be efficacious in reducing stroke re-
currence or progression, randomized trials (28) of the early
institution of heparin therapy have failed to show a signif-
icant reduction in rate of stroke recurrence or progression.
The effectiveness ofplatelet-active agents in the second-
ary prevention ofstroke recurrence after a completed stroke
has been examined with conflicting results. Many of the
studies of stroke prevention after a transient ischemic attack
have, in fact, included sizable numbers of patients with
small completed strokes. In one study (29) in which 85%
of the patients studied had had a completed stroke, a sig-
nificant benefit in favor of aspirin therapy was demonstrated.
Another more recent, large randomized trial (30) restricted
to patients with completed stroke failed to demonstrate any
benefit of aspirin in a dose of 1.5 g daily in the reduction
of stroke or death in treated patients. There is currently a
randomized clinical trial underway of ticlopidine therapy
after completed stroke to determine the effectiveness of this
platelet-active agent in reducing the frequency of stroke
recurrence.
In summary. the benefits of long-term antithrombotic
therapy after a completed stroke remain uncertain. Chronic
anticoagulant therapy appears to be associated with too great
a risk, and the benefit of aspirin therapy is controversial.
Until more studies are available, most patients will be man-
aged with careful attention to risk factors (such as hyper-
tension) and with aspirin, pending the results of studies of
other platelet-active agents.
Progressing stroke. The terms "progressing stroke" or
. 'stroke in evolution" describe the clinical situation in which
a patient's mild to moderate neurologic deficit worsens over
hours or a few days as a result of extension of brain in-
farction. There are multiple potential causes for deteriora-
tion in a patient's neurologic deficit, including edema in the
area of infarction, metabolic disturbances, hemorrhage into
an area of infarction and coexisting infectious or cardiac
disorders. About 20% of patients with an acute brain in-
farction will develop a progressing stroke pattern (28). Most
of these patients will exhibit their progression within the
first 48 hours after their stroke, especially those with a
carotid distribution infarct. Patients with vertebrobasilar dis-
tribution infarction are at least twice as likely to develop a
progressive stroke pattern and the period of risk extends to
5 to 7 days after the acute stroke (31-36).
Heparin therapy is generally recommended in patients
with progressing stroke provided that other causes for de-
terioration such as hemorrhage have been excluded. This
lACC Vol 8. No 6
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Table 4. Early Recurrent Embolism After Embolic Stroke
Cardiac No. of Interval Recurrence
Sludy (Reference)/Year Source Pallents (days) (%)
Brain and systemIC recurrence
Daly et al (50) RHD 194 7 17
1951
Szekely (51) RHD 72 28 10
1964
Darling et aL (52) RHD 89 14 19
1967
Fleming et al (53) RHD 125 30 14
1971
Santamana et aL (54) RHD 55 7 II
1983
Darlmg et aL (52) AF 59 14 20
1967
Hart et aL (55) AF 23 14 13
1983
Santamana et aL (54) AF 54 7 7
1983
Fisher (56) AF/RHD 100 10 5
1979
Sherman et aL (57) AF/RHD 46 14 13
1984
Darlmg et aL (52) MI 28 14 18
1967
Santamana et aL (54) PVR II 7 9
1983
Shields et aL (58) MIxed 40 7 5
1984
Only brain recurrence
CESG (12) MIxed 21 14 10
1983
Furlan et aL (59) Mixed 23 7 22
1982
Koller (60) Mixed 29 14 14
1982
Bass (61) MIxed 30 30 10
1983
Sage and Van Ultert (62) AF 59 14 2
1983
Calandre et aL (63) RHD 15 14 0
1983
AF = atnal fibnllation; CESG = Cerebral Embolism Study Group; MI = myocardial mfarcllon;
PVR = prosthellc valve replacement; RHD = rheumallc heart disease
recommendation is based on two small randomized clinical
trials which suggest that further progression may be reduced
by half in patients on anticoagulant therapy. However, both
of the studies antedated modern methodologic standards of
clinical trials and involved small numbers of patients. non-
blinded end points and incomplete definition of entry and
end point criteria. If heparin is effective in improving the
outcome of patients with progressing stroke, it has been
assumed that it might also prevent the development of pro-
gressing stroke when administered early after a mild or
moderate brain infarction. However, a recent randomized
trial of heparin (28) showed that 18.9% of patients not
receiving heparin experienced progression compared with
15.3% of those receiving heparin. These values were not
significantly different.
Transient ischemic attack. Anticoagulant therapy. Four
randomized prospective studies (19,20,37,38) have exam-
ined the efficacy of anticoagulant therapy in patients with
transient ischemic attacks. These studies showed no differ-
ence between the anticoagulant-treated and untreated pa-
tients; however, there was a combined total of only 93
patients in the treated group and 85 in the control group
(Table 1). The occurrence of stroke was about the same in
each group, and there was a trend for increased mortality
for those patients treated with anticoagulants. This increase
in mortality rate in patients receiving anticoagulant therapy
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was also found in the cooperative study (39) of hospital
frequency of transient ischemic attacks.
In summary, it has not been clearly established whether
anticoagulant therapy effectively reduces stroke risk after a
transient ischemic attack. The increased mortality with long-
term anticoagulant use in these patients suggests that long-
term anticoagulation for transient ischemic attacks should
not be used routinely.
Platelet-active agents. Several studies have examined
the effectiveness of platelet-active agents including aspirin,
sulfinpyrazone and dipyridamole in patients with a transient
ischemic attack (Table 2). Eight studies (29,40-46) com-
pared aspirin with placebo or some other antithrombotic
therapy. The two largest of these studies showed a reduction
in stroke and death of 31 % (39) and 45% (29). All of these
studies used aspirin in doses of 1,000 to 1,500 mg/day.
Studies examining the efficacy of lower doses of aspirin are
now underway. In two of the trials (40,43), men treated
with aspirin experienced a greater reduction in stroke risk
than did women. The effectiveness of sulfinpyrazone has
been examined in both Canadian and Italian trials (40,43)
with interesting trends noted. In the Canadian trial (40),
stroke and death occurred less frequently in the group re-
ceiving both aspirin and sulfinpyrazone. In the Italian study
(43), there was a trend in women for sulfinpyrazone to be
more beneficial than aspirin. Dipyridamole has been studied
alone and in combination with aspirin and has not been
shown to produce any benefit in patients with a transient
ischemic attack or minor stroke (Table 3) (29,47-49). A
large cooperative study is currently in progress comparing
aspirin with ticlopidine hydrochloride.
Figure 5. Outcome of a randomized trial of immediate antico-
agulant therapy in embolic stroke. Patients with a hemorrhagic
infarct on initial computed tomography (CT) or with acute hy-
pertension were excluded.
EMBOLIC STROKE
(N 47)
+1st CT ---;~~ 2 hemorrhagIC infarcts
(both large)
In summary, according to previous randomized trials, it
is recommended that aspirin in a dose of I to 1.5 g/day be
administered to a patient with a transient ischemic attack.
Future studies may clarify the issues of smaller doses of
aspirin, any sex differences in responsiveness and the use-
fulness of other platelet-active agents under investigation.
Cardiogenic Brain Embolism
The decision about the use and timing of anticoagulation
after cardiogenic embolism is based on the relative benefits
of anticoagulation in preventing recurrent embolism versus
the risks of increased hemorrhagic complications. The in-
formation needed to make such a decision includes the rate
and timing of recurrent embolism, the risks of hemorrhage
with anticoagulant use and the nature of any subgroups at
particularly increased risk for either recurrent embolus or
hemorrhage. Cardioembolic strokes are at particular risk of
secondary hemorrhage into the infarct, presumably because
distal migration of the embolus from its original site of
occlusion results in reperfusion of the infarcted tissue (Fig.
2, 3 and 4).
Risk of recurrence. Approximately 12% of patients with
cardiogenic brain embolism will experience a recurrence
within 2 weeks of their embolic stroke. This rate of recur-
rence is based on some 15 studies (12,50-63) with rates of
recurrence that range from 2 to 22% (Table 4). The risk of
early recurrent emboli appears to be similar in most major
cardiac causes of brain embolism including atrial fibrilla-
tion, ischemic heart disease and rheumatic heart disease.
Two retrospective studies (56,62) reported lower rates of
Figure 6. Management scheme for anticoagulant therapy of a
patient with embolic stroke. CT = computed tomography.
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early recurrence in patients with nonvalvular atrial fibril-
lation, while other studies demonstrated little difference be-
tween nonvalvular atrial fibrillation and other cardiac sources
of brain embolism.
Heparin. Immediate heparin administration appears to
reduce the rate of recurrent embolism to about one-third
that in patients not receiving anticoagulants (55,58-63). The
single randomized trial (55) included only 45 patients and
demonstrated a lower recurrence rate in patients receiving
anticoagulants (Fig. 5).
Risk of brain hemorrhage. Fear of a symptomatic brain
hemorrhage is the major deterrent to immediate anticoag-
ulant therapy in patients with cardiogenic brain embolus.
There is a paucity of well designed clinical studies address-
ing the issue of the risk of brain hemorrhage in these pa-
tients. Several studies (12,55,59,60,64,65) with an aggre-
gate of 162 patients receiving immediate anticoagulant
therapy reported no hemorrhagic worsening. Other studies
(58,61,63,66) reported hemorrhagic worsening in from 1.4
to 16% of patients given immediate anticoagulant therapy.
This variability in the risk of brain hemorrhage suggests
there may be subpopulations of patients at greater or lesser
risk for anticoagulation-induced brain hemorrhage.
Hemorrhagic infarction. Hemorrhagic infarction oc-
curs in from 5 to 15% of patients with cardiogenic brain
embolism independent of their anticoagulant therapy
(12,13,67). Hemorrhagic infarction occurs when there is
extravasation of blood into an area of brain infarction such
that the blood and ischemic brain tissue occupy the region
of infarction. The presumed mechanism of hemorrhagic in-
farction formation is occlusion of a brain artery, producing
ischemic damage to the brain and vascular endothelium
followed by reestablishment of blood flow (Fig. 2, 3 and
4). Blood then seeps through damaged vascular endothe-
lium, producing varying degrees of hemorrhagic infarction,
from small amounts of microscopic hemorrhage invisible to
the computed tomographic scan to larger quantities of blood
visible as mottled areas of increased density on computed
tomography or as large confluent collections of hematoma
within an infarct causing a mass effect and clinical wors-
ening. There seems little doubt that these latter large and
often lethal brain hemorrhages are overrepresented in the
published studies by virtue of the fact that these patients are
studied more extensively and are more apt to die, thus be-
coming part of an autopsy series. In a series (68) of 62
cases of hemorrhagic infarction, 45 had no evidence of
clinical worsening in association with the development of
hemorrhagic infarction. Seventeen (27%) of the 62 patients
had clinical worsening in conjunction with the development
of brain hemorrhage as determined by computed tomogra-
phy. These patients had a variety of underlying cardiac
disorders, suggesting no predisposition of certain cardiac
abnormalities to their production of hemorrhagic infarction.
Large cerebral infarcts occurred in about 60% of patients
who developed brain hemorrhage with clinical worsening
and in only about 20% of the patients without hemorrhagic
worsening. Thus, it would appear that one of the major
determinants of the development of hemorrhagic infarction
is the size of brain infarction. Large infarcts are more likely
to undergo hemorrhagic transformation with or without an-
ticoagulants. If a patient is receiving anticoagulant therapy
when the infarct undergoes hemorrhagic transformation, he
or she is more likely to experience clinically significant brain
hemorrhage than asymptomatic hemorrhagic transformation
(13,58,69,70).
Hemorrhagic infarction does not occur immediately, but
awaits the lysis of the embolus and reperfusion of the isch-
emic brain. Thus, a computed tomographic scan obtained
immediately after a brain embolus rarely shows evidence
of hemorrhagic infarction, whereas a scan done several days
after the embolic stroke shows hemorrhagic infarction in up
to 15% of these patients. An analysis of the timing of hem-
orrhagic infarction suggests that most but not all hemor-
rhagic infarctions occur within the first 48 hours after an
embolic stroke. The therapeutic implication of this obser-
vation is that computed tomography performed in the first
12 hours after an embolic stroke cannot effectively exclude
the majority of patients who are likely to undergo hemor-
rhagic transformation. On the other hand, computed to-
mography done 36 to 48 hours after an embolic stroke will
identify the majority of patients who are destined to undergo
hemorrhagic transformation. In the series (68) of 62 cases,
the group of patients with symptomatic brain hemorrhage
not only did have a higher frequency of large infarcts, but
also a larger number of them underwent immediate heparin
therapy based on a nonhemorrhagic computed tomographic
scan obtained within the first 12 hours. Excessive antico-
agulation was a poor predictor of the risk of brain hemor-
rhage with clinical worsening in these patients.
Anticoagulant Therapy in Cardiogenic
Brain Embolism
Certain management recommendations can be made based
on the assumption that a group of patients at increased risk
for brain hemorrhage after an embolic stroke can be iden-
tified. This group includes those with large infarcts and those
destined to develop hemorrhagic infarction within the first
48 hours. A patient with a suspected cardiogenic brain em-
bolus should not receive immediate anticoagulant therapy.
Computed tomography should be done between 24 and 48
hours from onset, and if the patient is found to have a
hemorrhagic infarct or a large infarct, anticoagulation should
be delayed for 7 to 10 days (Fig. 6) Anticoagulation should
also be delayed in patients with sustained elevations in blood
pressure (that is, > 1801100 mm Hg). Patients with a small
or medium-sized infarct, no evidence of hemorrhage by
computed tomography and no sustained hypertension should
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receive heparin. It is hoped that this course of management
will provide anticoagulant protection against recurrent em-
bolism in the majority of patients with a recent cardiogenic
embolus without subjecting the group at increased risk of
hemorrhagic infarction to the additional risk of anticoagulant
therapy.
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